UBS Sticks to Its Hold Rating for Roche Holding AG (RHHVF)

TipRanks13:25 ET

TG Therapeutics Wins VA Contract for Briumvi

Seeking Alpha13:15 ET

Roche's Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial

Roche (ROG.SW, RO.SW) on Wednesday said the subcutaneous formula of Ocrevus showed nearly complete suppression of clinical relapses and brain lesions in multiple sclerosis patients at 48 weeks, citing updated late-stage data.

MT NewswiresApr 17 05:47 ET

Analysts Offer Insights on Healthcare Companies: APONTIS PHARMA AG (DE:APPH), Roche Holding AG (OtherRHHVF) and Zur Rose Group AG (Six Swiss: CH:DOCM)

TipRanksApr 17 05:03 ET

Roche's Subcutaneous OCREVUS One-year Data Demonstrates Near-complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks.

GlobeNewswireApr 17 02:00 ET

As More Rare Disease Therapies Launch, Their Prices Are Rising

Seeking AlphaApr 16 12:22 ET